Neoadjuvant Chemotherapy for Colon Cancer

Abstract

Glioblastoma multiforme (GBM) is the most common and devastating type of primary brain tumor, with a median survival time of only 15 months. Having a clinically applicable genetic biomarker would lead to a paradigm shift in precise diagnosis, personalized therapeutic decisions, and prognostic prediction for GBM. Radiogenomic profiling connecting radiological imaging features with molecular alterations will offer a noninvasive method for genomic studies of GBM. To this end, we analyzed over 3800 glioma and GBM cases across four independent datasets. The Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) databases were employed for RNA-Seq analysis, whereas the Ivy Glioblastoma Atlas Project (Ivy-GAP) and The Cancer Imaging Archive (TCIA) provided clinicopathological data. The Clinical Proteomic Tumor Analysis Consortium Glioblastoma Multiforme (CPTAC-GBM) was used for proteomic analysis. We identified a simple three-gene transcriptome signature—SOCS3, VEGFA, and TEK—that can connect GBM’s overall prognosis with genes’ expression and simultaneously correlate radiographical features of perfusion imaging with SOCS3 expression levels. More importantly, the rampant development of neovascularization in GBM offers a promising target for therapeutic intervention. However, treatment with bevacizumab failed to improve overall survival. We identified SOCS3 expression levels as a potential selection marker for patients who may benefit from early initiation of angiogenesis inhibitors.

Development and Validation of a Novel Gene Signature for Predicting the Prognosis by Identifying m5C Modification Subtypes of Cervical Cancer

“…In multiple myeloma, high expression of FNDC3A can lead to ROS accumulation, ATP deficiency and cell death in multiple myeloma cells. VEGFA can be used as a prognostic biomarker for head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, glioblastoma and papillary thyroid carcinoma (He et al, 2020;Stuchi et al, 2020;Yang et al, 2020;Zheng and Tao, 2020). Downregulation of VEGFA expression can inhibit the proliferation, angiogenesis and metastasis of osteosarcoma cells, ovarian cancer and lung squamous cell carcinoma (Chen et al, 2020a;Chen et al, 2020b;Li et al, 2020;Qin et al, 2020).…”

Gold (III) Derivatives in Colon Cancer Treatment

“…This article is limited to gold compounds acting on human CRC cell lines, which might poorly represent the clinical disease. However, especially in CRC surgical treatment, neoadjuvant and adjuvant therapy is applied to reduce the micrometastatic area, and in this context, cell-based assays, especially clonogene assays, can mimic the in vivo situation [ 35 ]. We are observing a significant increase in publications on gold complexes.…”

“…In context of CRC therapy, the clinical prospective data on neoadjuvat therapy is limited—patients can benefit from these treatments [ 35 ], however the limitations are side effects such as neuropathy induced by oxaliplatin—that force for the invention of better and safer alternatives, such as other metallodrugs, including gold complexes [ 29 ].…”

Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies

“…In biomedical research, there is an active area of interest in novel treatment strategies that can be used to treat locally advanced disease in CRC. In this regard, an increasing body of evidence has shown that neoadjuvant chemotherapy (defined as chemotherapy administered to treat tumors before surgical resection) is able to reduce tumor size, facilitate resection, and improve completion rates in CRC 4 , [5] , [6] , 7 . The standard of care in neoadjuvant chemotherapy (NAC) consists in the use of maximum-tolerated doses (MTDs) of a cytotoxic drug.…”